Cabozantinib is evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4 for a wide array of oncological indications, including renal cell carcinoma, neuroendocrine tumors, metastatic colorectal cancer, soft-tissue sarcomas, and pediatric malignancies like Ewing sarcoma. Sponsored by academic medical centers and industry partners, these monotherapy and combination studies display varied recruitment statuses, including recruiting, active not recruiting, and completed. Representative protocols encompass Phase 2 trials for renal cell carcinoma brain metastases and Phase 1 studies in colorectal carcinoma.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07405164 | RECRUITING | Von Hippel-Lindau Disease; Malignant Neoplasms |
Merck Sharp & Dohme LLC |
2026-03-23 | PHASE3 |
| NCT06502171 | RECRUITING | Neurofibromatosis 1; Plexiform Neurofibroma |
Girish Dhall, MD |
2026-06-09 | PHASE1 |
| NCT07383441 | RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
SWOG Cancer Research Network |
2026-06-05 | PHASE3 |
| NCT06364631 | RECRUITING | Metastatic Kidney Cancer; Metastatic Kidney Carcinoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-04-12 | PHASE3 |
| NCT07227402 | RECRUITING | Renal Cell Carcinoma |
Merck Sharp & Dohme LLC |
2025-11-26 | PHASE3 |
| NCT07194044 | RECRUITING | Metastatic Ewing Sarcoma |
H. Lee Moffitt Cancer Center and Research Institute |
2026-02-05 | PHASE1 |
| NCT06475989 | RECRUITING | Refractory Differentiated Thyroid Gland Carcinoma |
ECOG-ACRIN Cancer Research Group |
2024-08-22 | PHASE3 |
| NCT06726421 | RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic |
Sun Yat-sen University |
2024-09-18 | PHASE3 |
| NCT07620574 | ENROLLING_BY_INVITATION | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer |
Exelixis |
2026-07-30 | PHASE3 |
| NCT07805122 | RECRUITING | Renal Cell Carcinoma |
Centro di Riferimento Oncologico - Aviano |
2026-05-19 | |
| NCT05691478 | SUSPENDED | High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma |
National Cancer Institute (NCI) |
2023-03-03 | PHASE2; PHASE3 |
| NCT07293351 | RECRUITING | Advanced Renal Cell Carcinoma (RCC) |
Bristol-Myers Squibb |
2026-03-26 | PHASE1; PHASE2 |
| NCT03899155 | RECRUITING | Cancer |
Bristol-Myers Squibb |
2019-08-09 | PHASE2 |
| NCT05092958 | ACTIVE_NOT_RECRUITING | Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8 |
National Cancer Institute (NCI) |
2022-06-03 | PHASE3 |
| NCT06900595 | RECRUITING | Locally Advanced Adrenal Cortical Carcinoma; Metastatic Adrenal Cortical Carcinoma; Recurrent Adrenal Cortical Carcinoma; Stage III Adrenal Cortical Carcinoma AJCC v8; Stage IV Adrenal Cortical Carcinoma AJCC v8; Unresectable Adrenal Cortical Carcinoma |
National Cancer Institute (NCI) |
2026-02-22 | PHASE2 |
| NCT05773274 | RECRUITING | Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Digestive System Neuroendocrine Tumor G2; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Digestive System Neuroendocrine Tumor G2 |
National Cancer Institute (NCI) |
2024-01-12 | PHASE2 |
| NCT05536141 | RECRUITING | Clear Cell Renal Cell Carcinoma; Solid Tumors |
Arcus Biosciences, Inc. |
2022-10-26 | PHASE1 |
| NCT07028125 | RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Metastatic Renal Cell Carcinoma; Locally Advanced |
Centre Francois Baclesse |
2025-10-01 | PHASE4 |
| NCT05613413 | RECRUITING | Metastatic Squamous Non-Small Cell Lung Carcinoma |
University of Illinois at Chicago |
2022-12-28 | PHASE2 |
| NCT03768063 | ACTIVE_NOT_RECRUITING | Cancer |
Hoffmann-La Roche |
2019-02-28 | PHASE3 |
| NCT03539822 | RECRUITING | Gastric Cancer; Esophageal Adenocarcinoma; Hepatocellular Carcinoma; Colorectal Cancer |
Anwaar Saeed |
2018-10-22 | PHASE1; PHASE2 |
| NCT05904080 | SUSPENDED | Metastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8 |
National Cancer Institute (NCI) |
2024-02-19 | PHASE2 |
| NCT05327686 | RECRUITING | Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma |
NRG Oncology |
2023-02-01 | PHASE2 |
| NCT07151326 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC) |
National Health Research Institutes, Taiwan |
2025-09 | PHASE2 |
| NCT07011719 | RECRUITING | Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma |
Arcus Biosciences, Inc. |
2025-09-08 | PHASE3 |
| NCT06934057 | RECRUITING | Kidney Cancer; Renal Cell Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-05-16 | PHASE4 |
| NCT03816345 | RECRUITING | Autoimmune Disease; Crohn Disease; Dermatomyositis; Hematopoietic and Lymphoid Cell Neoplasm; Inflammatory Bowel Disease; Malignant Solid Neoplasm; Multiple Sclerosis; Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Sjogren Syndrome; Systemic Lupus Erythematosus; Systemic Scleroderma; Ulcerative Colitis |
National Cancer Institute (NCI) |
2019-07-16 | PHASE1 |
| NCT03793166 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-06-07 | PHASE3 |
| NCT07010393 | NOT_YET_RECRUITING | Thyroid Neoplasms |
Fujian Medical University |
2025-07-01 | PHASE4 |
| NCT05039281 | ACTIVE_NOT_RECRUITING | Recurrent Glioblastoma; Recurrent Gliosarcoma |
M.D. Anderson Cancer Center |
2022-09-23 | PHASE1; PHASE2 |
| NCT05019703 | RECRUITING | Locally Advanced Osteosarcoma; Metastatic Osteosarcoma; Recurrent Osteosarcoma; Refractory Osteosarcoma; Unresectable Osteosarcoma |
M.D. Anderson Cancer Center |
2023-04-25 | PHASE2 |
| NCT05048212 | RECRUITING | Brain Metastases; Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2022-09-20 | PHASE2 |
| NCT04588051 | ACTIVE_NOT_RECRUITING | HCC |
Stephen Chan Lam |
2020-11-01 | PHASE2 |
| NCT06006013 | RECRUITING | Locally Advanced Adrenal Cortex Carcinoma; Adrenal Cortical Carcinoma; Stage III Adrenal Cortex Carcinoma; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma |
Emory University |
2025-01-15 | PHASE2 |
| NCT05327738 | WITHDRAWN | BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma |
OHSU Knight Cancer Institute |
2022-12-10 | PHASE2 |
| NCT05127824 | RECRUITING | Carcinoma, Renal Cell |
Jodi Maranchie |
2023-07-06 | PHASE2 |
| NCT05249114 | ACTIVE_NOT_RECRUITING | Neuroendocrine Tumors |
Providence Health & Services |
2022-12-28 | PHASE1 |
| NCT04878029 | RECRUITING | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma |
Emory University |
2021-07-23 | PHASE1 |
| NCT06132945 | ACTIVE_NOT_RECRUITING | Metastatic Renal Cell Carcinoma; Brain Metastases |
Memorial Sloan Kettering Cancer Center |
2023-11-10 | PHASE1 |
| NCT06156410 | RECRUITING | Ewing Sarcoma; Osteosarcoma; Sarcomas |
Children's Hospital of Philadelphia |
2023-10-24 | PHASE1 |
| NCT05663710 | RECRUITING | Advanced Cancer; Clear Cell Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2023-06-30 | PHASE1; PHASE2 |
| NCT05012371 | ACTIVE_NOT_RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2022-02-16 | PHASE2 |
| NCT04760288 | WITHDRAWN | Medullary Thyroid Cancer |
Hoffmann-La Roche |
2023-11-30 | PHASE3 |
| NCT05361720 | RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
Vanderbilt-Ingram Cancer Center |
2022-12-06 | PHASE2 |
| NCT07077161 | RECRUITING | Renal Cell Carcinoma (RCC) |
dr. Tom van der Hulle |
2026-01-26 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT06811116 | RECRUITING | Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8 |
National Cancer Institute (NCI) |
2025-11-17 | PHASE1; PHASE2 |
| NCT05048901 | RECRUITING | Neuroendocrine Tumors,Gastroenteropancreatic |
National Health Research Institutes, Taiwan |
2021-09-17 | PHASE1; PHASE2 |
| NCT03541902 | ACTIVE_NOT_RECRUITING | Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2018-05-15 | PHASE2 |
| NCT05111574 | ACTIVE_NOT_RECRUITING | Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma |
National Cancer Institute (NCI) |
2022-08-11 | PHASE2 |
| NCT05411081 | ACTIVE_NOT_RECRUITING | Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8 |
National Cancer Institute (NCI) |
2023-03-24 | PHASE2 |
| NCT01639508 | RECRUITING | Non-Small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2012-07 | PHASE2 |
| NCT04322955 | ACTIVE_NOT_RECRUITING | Kidney Cancer; Renal Cell Carcinoma |
Mark Stein |
2020-06-22 | PHASE2 |
| NCT07187869 | RECRUITING | Clear Cell Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2026-02-12 | PHASE1 |
| NCT05559879 | RECRUITING | Gynecologic Cancer; Carcinoma; Uterine Cancer; Endometrial Cancer |
University of Alabama at Birmingham |
2023-08-20 | PHASE1; PHASE2 |
| NCT05241561 | NOT_YET_RECRUITING | Cancer of Kidney |
Centre Hospitalier Universitaire de Besancon |
2022-06 | PHASE2 |
| NCT03866382 | RECRUITING | Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Papillary Renal Cell Carcinoma; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Urachal Adenocarcinoma; Urethral Clear Cell Adenocarcinoma |
National Cancer Institute (NCI) |
2019-05-13 | PHASE2 |
| NCT03634540 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney |
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2018-09-27 | PHASE2 |
| NCT04551430 | ACTIVE_NOT_RECRUITING | Metastatic Soft-tissue Sarcoma |
Washington University School of Medicine |
2021-01-05 | PHASE2 |
| NCT06835972 | RECRUITING | Metastatic Renal Cell Carcinoma; Translocation Renal Cell Carcinoma |
Memorial Sloan Kettering Cancer Center |
2025-02-14 | PHASE1; PHASE2 |
| NCT05122546 | ACTIVE_NOT_RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma |
City of Hope Medical Center |
2021-11-01 | PHASE1 |
| NCT05136196 | RECRUITING | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Melanoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Melanoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Unresectable Melanoma |
National Cancer Institute (NCI) |
2022-12-06 | PHASE2 |
| NCT06026410 | RECRUITING | Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC) |
Kura Oncology, Inc. |
2023-10-18 | PHASE1 |
| NCT04876456 | ACTIVE_NOT_RECRUITING | Germ Cell Tumor; Seminoma; Non-seminomatous Germ Cell Tumor; Ovarian Germ Cell Tumor |
Jennifer King |
2021-06-10 | PHASE2 |
| NCT04310007 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2020-07-13 | PHASE2 |
| NCT04413123 | ACTIVE_NOT_RECRUITING | Papillary Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Translocation Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Renal Cell Carcinoma; Unresectable Advanced Renal Cell Carcinoma; Metastatic Ncc Renal Cell Carcinoma |
Bradley A. McGregor, MD |
2020-11-05 | PHASE2 |
| NCT05425004 | RECRUITING | Meningioma |
Baptist Health South Florida |
2022-06-01 | PHASE2 |
| NCT05182164 | RECRUITING | Soft Tissue Sarcoma Adult; Advanced Soft-tissue Sarcoma; Ewing Sarcoma; Osteosarcoma; Undifferentiated Pleomorphic Sarcoma |
Institut Bergonié |
2022-04-25 | PHASE2 |
| NCT05263050 | RECRUITING | Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Neuroendocrine Tumors; Carcinoid Tumor |
Fox Chase Cancer Center |
2022-01-21 | PHASE2 |
| NCT05613894 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
University of Utah |
2023-07-14 | PHASE1 |
| NCT04071223 | ACTIVE_NOT_RECRUITING | Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma |
National Cancer Institute (NCI) |
2020-07-29 | PHASE2 |
| NCT04472767 | RECRUITING | Hepatocellular Carcinoma; HCC |
University of California, Irvine |
2020-08-07 | PHASE2 |
| NCT04116541 | RECRUITING | Malignant Solid Tumor |
Centre Leon Berard |
2020-01-28 | PHASE2 |
| NCT02496208 | ACTIVE_NOT_RECRUITING | Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma |
National Cancer Institute (NCI) |
2015-07-22 | PHASE1 |
| NCT04412629 | ACTIVE_NOT_RECRUITING | High Grade Neuroendocrine Neoplasms |
Washington University School of Medicine |
2020-11-24 | PHASE2 |
| NCT07015021 | NOT_YET_RECRUITING | Multiple Myeloma; Carfilzomib; Daratumumab; Pomalidomide |
The First Affiliated Hospital of Soochow University |
2025-06-01 | |
| NCT05931393 | RECRUITING | RCC; Renal Cell Carcinoma |
University of Texas Southwestern Medical Center |
2023-12-20 | PHASE2 |
| NCT05092373 | RECRUITING | Advanced Breast Carcinoma; Advanced Endometrial Carcinoma; Advanced Fallopian Tube Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Abdominal Neoplasm; Advanced Malignant Female Reproductive System Neoplasm; Advanced Malignant Thoracic Neoplasm; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Malignant Abdominal Neoplasm; Malignant Solid Neoplasm; Metastatic Breast Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Abdominal Neoplasm; Metastatic Malignant Female Reproductive System Neoplasm; Metastatic Malignant Thoracic Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Renal Cell Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2022-04-29 | PHASE1 |
| NCT03635892 | ACTIVE_NOT_RECRUITING | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma |
Memorial Sloan Kettering Cancer Center |
2018-08-13 | PHASE2 |
| NCT05502315 | ACTIVE_NOT_RECRUITING | Castration-resistant Prostate Cancer; Metastatic Cancer |
Rana McKay, MD |
2023-02-02 | PHASE2 |
| NCT05168618 | RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
University of Utah |
2022-03-29 | PHASE2 |
| NCT06535737 | NOT_YET_RECRUITING | Hepatocellular Carcinoma Non-resectable |
Chulalongkorn University |
2024-08 | PHASE2 |
| NCT05135975 | RECRUITING | Neuroblastoma; Sarcoma |
Nationwide Children's Hospital |
2022-07-20 | PHASE2 |
| NCT05168163 | RECRUITING | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma |
Academic and Community Cancer Research United |
2022-05-27 | PHASE2 |
| NCT05188118 | COMPLETED | Renal Cell Carcinoma |
Icahn School of Medicine at Mount Sinai |
2023-02-15 | EARLY_PHASE1 |
| NCT04204850 | RECRUITING | Hepatocellular Carcinoma; Recurrent Cancer; Liver Transplant |
University Health Network, Toronto |
2020-08-07 | PHASE2 |
| NCT05859217 | NOT_YET_RECRUITING | Lung Cancer; NSCLC Stage IV; Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced NSCLC |
Jun Zhang, MD, PhD |
2024-12 | PHASE2 |
| NCT05836571 | ACTIVE_NOT_RECRUITING | Locally Advanced Extraskeletal Myxoid Chondrosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Locally Advanced Unresectable Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Leiomyosarcoma; Unresectable Liposarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma |
National Cancer Institute LAO |
2023-10-25 | PHASE2 |
| NCT05038839 | COMPLETED | Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2022-02-09 | PHASE1 |
| NCT05797805 | RECRUITING | Advanced Hepatocellular Carcinoma |
Iterion Therapeutics |
2023-09-13 | PHASE1; PHASE2 |
| NCT06341712 | TERMINATED | Osteosarcoma; Osteosarcoma in Children; Osteosarcoma in Adolescents and Young Adults |
Ipsen |
2024-11-22 | PHASE2 |
| NCT04963283 | ACTIVE_NOT_RECRUITING | Colorectal Adenocarcinoma; Colon Cancer; Colon Adenocarcinoma; Rectum Cancer; Rectal Cancer; Rectal Adenocarcinoma; Colorectal Cancer |
University of Colorado, Denver |
2021-06-23 | PHASE2 |
| NCT03611595 | COMPLETED | Solid Tumor |
Peter Zage |
2018-08-28 | PHASE1 |
| NCT04820179 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer; Metastatic Pancreatic Cancer |
University of Arizona |
2021-10-12 | PHASE2 |
| NCT04586231 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2021-02-25 | PHASE3 |
| NCT06716853 | TERMINATED | Clear Cell RCC |
Genenta Science |
2024-10-22 | PHASE1; PHASE2 |
| NCT03899428 | RECRUITING | Hepatocellular Carcinoma |
Humanity & Health Medical Group Limited |
2019-05-02 | PHASE2 |
| NCT05660954 | COMPLETED | Differentiated Thyroid Cancer |
Grupo Espanol de Tumores Neuroendocrinos |
2023-05-25 | PHASE2 |
| NCT04289779 | ACTIVE_NOT_RECRUITING | Bladder Cancer |
Deepak Kilari |
2020-05-21 | PHASE2 |
| NCT04631744 | TERMINATED | Prostate Cancer |
Weill Medical College of Cornell University |
2021-03-03 | PHASE2 |
| NCT03367741 | ACTIVE_NOT_RECRUITING | Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 |
National Cancer Institute (NCI) |
2018-04-16 | PHASE2 |
| NCT04200443 | ACTIVE_NOT_RECRUITING | Metastatic Leiomyosarcoma; Metastatic Soft Tissue Sarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma; Unresectable Soft Tissue Sarcoma |
City of Hope Medical Center |
2020-01-14 | PHASE2 |
| NCT04339738 | ACTIVE_NOT_RECRUITING | Skin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral Angiosarcoma |
National Cancer Institute (NCI) |
2020-11-04 | PHASE2 |
| NCT05263245 | COMPLETED | Renal Cell Carcinoma |
dr. Tom van der Hulle |
2023-05-25 | PHASE2 |
| NCT04079712 | ACTIVE_NOT_RECRUITING | Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma |
National Cancer Institute (NCI) |
2020-08-06 | PHASE2 |
| NCT05289856 | COMPLETED | Cancer |
Johannes Gutenberg University Mainz |
2022-03-28 | PHASE2 |
| NCT04893785 | RECRUITING | Lung Neuroendocrine Neoplasm; GEP Neuroendocrine Tumor |
National Cancer Institute, Naples |
2021-06-15 | PHASE2 |
| NCT06171854 | UNKNOWN | Refractory Colorectal Adenocarcinoma |
University of Campania Luigi Vanvitelli |
2019-09-01 | PHASE2 |
| NCT04511455 | COMPLETED | Hepatocellular Carcinoma Non-resectable; Metastatic Hepatocellular Carcinoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2020-12-08 | PHASE2 |
| NCT03612232 | UNKNOWN | Adrenocortical Carcinoma |
Wuerzburg University Hospital |
2019-06-04 | PHASE2 |
| NCT03685448 | COMPLETED | Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma |
Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
2019-04-11 | PHASE2 |
| NCT06482086 | RECRUITING | Locally Advanced Thyroid Gland Carcinoma |
West China Hospital |
2021-06-01 | PHASE2 |
| NCT01658878 | COMPLETED | Hepatocellular Carcinoma |
Bristol-Myers Squibb |
2012-10-30 | PHASE1; PHASE2 |
| NCT02302833 | COMPLETED | Locally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Regional Adrenal Gland Pheochromocytoma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma |
M.D. Anderson Cancer Center |
2015-02-17 | PHASE2 |
| NCT04514484 | ACTIVE_NOT_RECRUITING | Advanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Prostate Carcinoma; Advanced Renal Cell Carcinoma; Advanced Thyroid Gland Medullary Carcinoma; Advanced Triple-Negative Breast Carcinoma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; HIV Infection; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Kaposi Sarcoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Thyroid Gland Medullary Carcinoma; Recurrent Triple-Negative Breast Carcinoma; Recurrent Urothelial Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 |
National Cancer Institute (NCI) |
2021-11-22 | PHASE1 |
| NCT05052723 | COMPLETED | Pancreatic Cancer |
Joseph Kim |
2022-01-04 | PHASE2 |
| NCT03967522 | COMPLETED | Metastatic Renal Cell Carcinoma |
Centre Leon Berard |
2019-11-29 | PHASE2 |
| NCT03914300 | ACTIVE_NOT_RECRUITING | Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma |
National Cancer Institute (NCI) |
2020-02-10 | PHASE2 |
| NCT04522908 | COMPLETED | Hepatocellular Carcinoma (HCC); Second Line Treatment |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2020-10-12 | PHASE2 |
| NCT04524208 | UNKNOWN | Neuroendocrine Tumors; Neuroendocrine Carcinoma |
Karsten Gavenis |
2021-03-01 | PHASE2 |
| NCT03425201 | COMPLETED | Urothelial Cancer |
Fundacion CRIS de Investigación para Vencer el Cáncer |
2019-10-14 | PHASE1; PHASE2 |
| NCT04767906 | COMPLETED | Hepatocellular Carcinoma |
University of Leipzig |
2021-12-14 | PHASE2 |
| NCT05007613 | COMPLETED | Esophageal Cancer; Metastatic Cancer; Squamous Cell Carcinoma |
National Taiwan University Hospital |
2021-06-23 | PHASE2 |
| NCT03667482 | COMPLETED | Head and Neck Squamous Cell Cancer; Recurrent Head and Neck Squamous Cell Cancer; Metastatic Head and Neck Squamous Cell Cancer |
Memorial Sloan Kettering Cancer Center |
2018-09-07 | PHASE1 |
| NCT05265988 | COMPLETED | Carcinoma Prostate |
Alfredo Berruti |
2021-11-29 | PHASE2 |
| NCT03957551 | TERMINATED | Advanced Metastatic Melanoma |
John Rieth |
2019-08-27 | PHASE1; PHASE2 |
| NCT04446117 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer; Prostate Adenocarcinoma |
Exelixis |
2020-10-19 | PHASE3 |
| NCT04220229 | TERMINATED | Sarcoma of the Extremity; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities; Stage II Soft Tissue Sarcoma of the Trunk and Extremities |
University of Washington |
2020-06-01 | PHASE1; PHASE2 |
| NCT02592356 | COMPLETED | Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma |
M.D. Anderson Cancer Center |
2015-11-16 | |
| NCT04540705 | COMPLETED | Renal Cell Carcinoma |
Bristol-Myers Squibb |
2020-09-11 | PHASE1 |
| NCT03370718 | COMPLETED | Metastatic Carcinoma in the Adrenal Cortex; Stage III Adrenal Cortex Carcinoma AJCC v8; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma |
M.D. Anderson Cancer Center |
2018-02-26 | PHASE2 |
| NCT04197310 | COMPLETED | Carcinoid Tumor; Carcinoid Tumor of GI System; Neuroendocrine Tumors |
Dana-Farber Cancer Institute |
2019-12-26 | PHASE2 |
| NCT04151563 | WITHDRAWN | Carcinoma, Non-small Cell Lung Cancer |
Bristol-Myers Squibb |
2021-04-15 | PHASE1; PHASE2 |
| NCT04164979 | COMPLETED | Gastric Adenocarcinoma; GastroEsophageal Cancer |
University of California, Irvine |
2020-02-04 | PHASE2 |
| NCT04400474 | COMPLETED | Neuroendocrine Tumor; Anaplastic Thyroid Cancer; Adenocarcinoma; Pheochromocytoma; Paraganglioma |
Grupo Espanol de Tumores Neuroendocrinos |
2020-10-07 | PHASE2 |
| NCT04134390 | COMPLETED | Old Age; Debility; Renal Carcinoma Metastatic |
Spanish Oncology Genito-Urinary Group |
2020-02-17 | PHASE2 |
| NCT04427787 | UNKNOWN | Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2020-06-20 | PHASE2 |
| NCT02761057 | COMPLETED | Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma |
National Cancer Institute (NCI) |
2016-07-25 | PHASE2 |
| NCT06156410 | Recruiting | Ewing Sarcoma|Osteosarcoma |
Children''s Hospital of Philadelphia|Children''s Hospital Colorado|Exelixis|Alex''s Lemonade Stand Foundation |
2023-10-24 | Phase 1 |
| NCT05200143 | TERMINATED | Refractory Cutaneous Melanoma |
Providence Health & Services |
2022-06-08 | PHASE2 |
| NCT04868773 | COMPLETED | Colorectal Cancer; Colorectal Carcinoma; Metastatic Cancer; CRC |
University of California, Irvine |
2021-07-16 | PHASE1 |
| NCT03375320 | ACTIVE_NOT_RECRUITING | Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm |
National Cancer Institute (NCI) |
2018-10-26 | PHASE3 |
| NCT04300140 | TERMINATED | Clear Cell Renal Cell Carcinoma |
Aravive, Inc. |
2021-02-26 | PHASE1; PHASE2 |
| NCT04091750 | ACTIVE_NOT_RECRUITING | Melanoma |
Georgetown University |
2020-03-02 | PHASE2 |
| NCT03534804 | COMPLETED | Metastatic Urothelial Carcinoma; Bladder Cancer |
University of Utah |
2018-09-18 | PHASE2 |
| NCT04454762 | UNKNOWN | Hepatocellular Carcinoma |
Johannes Gutenberg University Mainz |
2020-07-22 | PHASE2 |
| NCT03239015 | UNKNOWN | Rare Tumor; Refractory Tumor |
Baodong Qin |
2017-01-01 | PHASE2 |
| NCT04435977 | UNKNOWN | Hepatocarcinoma |
Istituto Clinico Humanitas |
2020-01-30 | PHASE2 |
| NCT04211337 | ACTIVE_NOT_RECRUITING | Medullary Thyroid Cancer |
Loxo Oncology, Inc. |
2020-02-11 | PHASE3 |
| NCT03945773 | COMPLETED | Locally Advanced or Metastatic Renal Cell Carcinoma |
Ipsen |
2020-01-08 | PHASE2 |
| NCT05039736 | WITHDRAWN | Hepatocellular Carcinoma; Liver Cancer |
M.D. Anderson Cancer Center |
2023-02-24 | PHASE2 |
| NCT04497038 | TERMINATED | Advanced Adult Hepatocellular Carcinoma |
University of Michigan Rogel Cancer Center |
2021-08-06 | PHASE1; PHASE2 |
| NCT03798626 | COMPLETED | Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma |
Novartis Pharmaceuticals |
2019-05-22 | PHASE1 |
| NCT04714697 | UNKNOWN | Renal Cell Cancer |
Asan Medical Center |
2021-03-01 | PHASE2 |
| NCT04316182 | COMPLETED | Hepatocellular Carcinoma |
Fundacion Clinic per a la Recerca Biomédica |
2020-07-31 | PHASE2 |
| NCT03170960 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Hepatocellular Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Colorectal Cancer; Head and Neck Cancer; Differentiated Thyroid Cancer; Lower Esophageal Cancer |
Exelixis |
2017-09-05 | PHASE1 |
| NCT03824691 | UNKNOWN | Bladder Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2019-09-25 | PHASE2 |
| NCT04205799 | COMPLETED | Advanced/Metastatic Cervical Cancer |
Centre Francois Baclesse |
2020-01-15 | PHASE2 |
| NCT04338269 | TERMINATED | Carcinoma, Renal Cell |
Hoffmann-La Roche |
2020-07-28 | PHASE3 |
| NCT03149822 | COMPLETED | Metastatic Renal Cell Carcinoma |
University of Colorado, Denver |
2017-09-28 | PHASE1; PHASE2 |
| NCT05249114 | Active not recruiting | Neuroendocrine Tumors |
Providence Health & Services|Exelixis|Advanced Accelerator Applications SA |
2022-12-28 | Phase 1 |
| NCT04661852 | COMPLETED | Relapsed Ewing Sarcoma; Refractory Ewing Sarcoma; Relapsed Osteosarcoma; Refractory Osteosarcoma |
Dana-Farber Cancer Institute |
2020-12-23 | PHASE1 |
| NCT04471428 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Hoffmann-La Roche |
2020-10-01 | PHASE3 |
| NCT05444933 | Completed | Advanced Renal Cell Carcinoma |
Ipsen |
2022-09-16 | -- |
| NCT02795156 | COMPLETED | Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon; Upper Aerodigestive Tract Carcinoma |
SCRI Development Innovations, LLC |
2016-09-28 | PHASE2 |
| NCT06377722 | TERMINATED | Renal Cell Carcinoma Metastatic; Renal Cell Carcinoma Stage IV; Renal Cell Carcinoma Stage III |
Fundacion Oncosur |
2018-11-01 | PHASE2 |
| NCT03943602 | UNKNOWN | Penile Squamous Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2019-08-01 | PHASE2 |
| NCT01979393 | COMPLETED | Uterine Sarcoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2015-02-02 | PHASE2 |
| NCT03468985 | COMPLETED | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2018-05-07 | PHASE2 |
| NCT03468218 | ACTIVE_NOT_RECRUITING | Metastatic Head and Neck Carcinoma; Paranasal Sinus Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7; Unresectable Head and Neck Squamous Cell Carcinoma |
Emory University |
2018-09-18 | PHASE2 |
| NCT02041260 | UNKNOWN | Differentiated Thyroid Cancer (DTC); Poorly Differentiated Thyroid Cancer |
Thomas Jefferson University |
2014-01 | PHASE2 |
| NCT04173338 | TERMINATED | Non Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Urothelial Carcinoma; Malignant Mesothelioma |
Augusta University |
2020-01-23 | PHASE1 |
| NCT02101736 | COMPLETED | NF1; Neurofibromatosis; Plexiform Neurofibromas |
University of Alabama at Birmingham |
2014-06 | PHASE2 |
| NCT04230954 | TERMINATED | Cervical Cancer; Recurrent Cervical Cancer; Metastatic Cervical Cancer; Persistent Cervical Cancer |
University of South Alabama |
2020-04-16 | PHASE2 |
| NCT04022343 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 |
Emory University |
2019-08-06 | PHASE2 |
| NCT03937219 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma |
Exelixis |
2019-06-25 | PHASE3 |
| NCT03729245 | TERMINATED | Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
Nektar Therapeutics |
2018-12-18 | PHASE3 |
| NCT04442581 | TERMINATED | Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma |
University of Washington |
2021-04-20 | PHASE2 |
| NCT03755791 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
Exelixis |
2018-06-10 | PHASE3 |
| NCT03963206 | COMPLETED | Hepatocellular Carcinoma |
Hospices Civils de Lyon |
2019-09-09 | PHASE4 |
| NCT04477512 | COMPLETED | Metastatic Hormone Refractory Prostate Cancer |
Washington University School of Medicine |
2021-02-19 | PHASE1 |
| NCT01466036 | COMPLETED | Carcinoid Tumor; Pancreatic Neuroendocrine Tumor |
Dana-Farber Cancer Institute |
2012-07 | PHASE2 |
| NCT04066595 | TERMINATED | Urothelial Carcinoma |
Johannes Gutenberg University Mainz |
2020-02-10 | PHASE2 |
| NCT02867592 | ACTIVE_NOT_RECRUITING | Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Renal Cell Carcinoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Medullary Carcinoma; Refractory Wilms Tumor; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor |
National Cancer Institute (NCI) |
2017-05-18 | PHASE2 |
| NCT03964337 | TERMINATED | Prostate Cancer; Prostate Cancer Adenocarcinoma; Non-Metastatic |
Duke University |
2020-03-17 | PHASE2 |
| NCT03201250 | TERMINATED | Multiple Myeloma; Refractory Multiple Myeloma; Relapsed/Refractory Multiple Myeloma |
University of Nebraska |
2018-02-21 | PHASE1; PHASE2 |
| NCT03463681 | COMPLETED | Metastatic Renal Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-06-11 | PHASE2 |
| NCT01630590 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
2014-01-08 | PHASE2 |
| NCT04149275 | WITHDRAWN | Carcinosarcoma of Ovary; Carcinosarcoma of Uterus; Carcinosarcoma of Vagina |
University of Alabama at Birmingham |
2021-02 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT03354884 | COMPLETED | Collecting Duct Carcinoma (Kidney) |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-01-12 | PHASE2 |
| NCT03542877 | COMPLETED | Colorectal Cancer |
Academic Thoracic Oncology Medical Investigators Consortium |
2018-06-01 | PHASE2 |
| NCT01755195 | COMPLETED | Refractory Soft Tissue Sarcomas |
National Cancer Institute (NCI) |
2013-01-15 | PHASE2 |
| NCT03911193 | UNKNOWN | Non-Small Cell Lung Cancer |
Fondazione Ricerca Traslazionale |
2018-09-21 | PHASE2 |
| NCT03428217 | COMPLETED | Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
Calithera Biosciences, Inc |
2018-04-24 | PHASE2 |
| NCT02885324 | TERMINATED | Glioblastoma Multiforme; Anaplastic Astrocytoma; Malignant Brain Tumor; High Grade Glioma |
Indiana University |
2017-05-18 | PHASE2 |
| NCT03339219 | COMPLETED | Advanced Renal Cell Carcinoma |
Takeda |
2017-12-13 | PHASE2 |
| NCT03690388 | ACTIVE_NOT_RECRUITING | Differentiated Thyroid Cancer |
Exelixis |
2018-10-05 | PHASE3 |
| NCT04131543 | UNKNOWN | Non Small Cell Lung Cancer |
University of Bologna |
2019-08-07 | PHASE2 |
| NCT01896479 | ACTIVE_NOT_RECRUITING | Medullary Thyroid Cancer |
Exelixis |
2015-02-25 | PHASE4 |
| NCT03200587 | COMPLETED | Renal Cell Carcinoma |
University of Utah |
2018-06-21 | PHASE1 |
| NCT03141177 | COMPLETED | Renal Cell Carcinoma |
Bristol-Myers Squibb |
2017-07-23 | PHASE3 |
| NCT03867045 | TERMINATED | Metastatic Renal Cell Carcinoma Treated With Cabozantinib |
Duke University |
2019-08-21 | |
| NCT03299946 | COMPLETED | Locally Advanced Hepatocellular Carcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-05-14 | PHASE1 |
| NCT03630120 | TERMINATED | Thyroid Cancer; Thyroid Cancer, Medullary; Differentiated Thyroid Cancer; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Poorly Differentiated Thyroid Gland Carcinoma |
H. Lee Moffitt Cancer Center and Research Institute |
2018-08-06 | PHASE2 |
| NCT03729297 | TERMINATED | Salivary Gland Cancer |
Radboud University Medical Center |
2018-09-05 | PHASE2 |
| NCT01935934 | COMPLETED | Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Metastatic Endometrioid Adenocarcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Uterine Corpus Carcinosarcoma |
National Cancer Institute (NCI) |
2013-05-08 | PHASE2 |
| NCT03316586 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2017-11-30 | PHASE2 |
| NCT02132598 | TERMINATED | Non Small Cell Lung Cancer (NSCLC); Metastases to the Brain |
Liza Villaruz, MD |
2015-12 | PHASE2 |
| NCT03586973 | COMPLETED | Advanced Hepatocellular Carcinoma |
Takeda |
2018-08-06 | PHASE2 |
| NCT02243605 | ACTIVE_NOT_RECRUITING | Metastatic Ewing Sarcoma; Metastatic Osteosarcoma; Recurrent Ewing Sarcoma; Recurrent Osteosarcoma; Stage III Osteosarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Unresectable Ewing Sarcoma; Unresectable Osteosarcoma |
National Cancer Institute (NCI) |
2014-12-19 | PHASE2 |
| NCT01822522 | COMPLETED | Advanced Malignant Solid Neoplasm; HIV Infection; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Unresectable Solid Neoplasm |
National Cancer Institute (NCI) |
2013-06-21 | PHASE1 |
| NCT02216578 | COMPLETED | Metastatic Gastrointestinal Stromal Tumor |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-02-02 | PHASE2 |
| NCT03213626 | TERMINATED | Pancreatic Adenocarcinoma Metastatic |
Patrick Joseph Loehrer Sr. |
2017-10-13 | PHASE2 |
| NCT02315430 | COMPLETED | Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2015-04-01 | PHASE2 |
| NCT01812668 | COMPLETED | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Barbara Ann Karmanos Cancer Institute |
2013-03 | |
| NCT02260531 | COMPLETED | Breast Cancer; Brain Tumor - Metastatic |
Dana-Farber Cancer Institute |
2014-11 | PHASE2 |
| NCT01709435 | COMPLETED | Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; Thyroid Gland Medullary Carcinoma |
National Cancer Institute (NCI) |
2012-11-14 | PHASE1 |
| NCT01683994 | COMPLETED | Prostatic Neoplasms |
National Cancer Institute (NCI) |
2012-09-07 | PHASE1; PHASE2 |
| NCT02008383 | COMPLETED | Colorectal Cancer |
John Strickler, M.D. |
2014-01 | PHASE1 |
| NCT01866410 | COMPLETED | Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7 |
National Cancer Institute (NCI) |
2013-05-20 | PHASE2 |
| NCT01688999 | COMPLETED | Urothelial Carcinoma; Urethral Neoplasms; Urinary Bladder Neoplasms; Kidney Neoplasms |
National Cancer Institute (NCI) |
2012-09-11 | PHASE2 |
| NCT01599793 | COMPLETED | Bone Metastases; Castrate-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
University of Chicago |
2012-05 | PHASE2 |
| NCT01908426 | COMPLETED | Hepatocellular Carcinoma |
Exelixis |
2013-09-26 | PHASE3 |
| NCT02293980 | ACTIVE_NOT_RECRUITING | ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma |
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2014-11-25 | PHASE1 |
| NCT01588821 | COMPLETED | Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers) |
Massachusetts General Hospital |
2012-06 | PHASE2 |
| NCT01441947 | COMPLETED | Breast Cancer |
Massachusetts General Hospital |
2011-10 | PHASE2 |
| NCT01835145 | COMPLETED | Recurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Uveal Melanoma AJCC v7 |
National Cancer Institute (NCI) |
2013-07-31 | PHASE2 |
| NCT01866293 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2013-05-28 | PHASE1; PHASE2 |
| NCT01834651 | COMPLETED | Prostate Cancer |
Edwin Posadas, MD |
2013-04-30 | PHASE2 |
| NCT01961765 | COMPLETED | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Massachusetts General Hospital |
2013-11 | PHASE1 |
| NCT01835158 | COMPLETED | Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2013-07-08 | PHASE2 |
| NCT02036476 | TERMINATED | Merkel Cell Carcinoma; Skin Cancer |
Dana-Farber Cancer Institute |
2014-02 | PHASE2 |
| NCT01708954 | ACTIVE_NOT_RECRUITING | Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2013-02-13 | PHASE2 |
| NCT01811212 | COMPLETED | Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage I Thyroid Gland Follicular Carcinoma; Stage I Thyroid Gland Papillary Carcinoma; Stage II Thyroid Gland Follicular Carcinoma; Stage II Thyroid Gland Papillary Carcinoma; Stage III Thyroid Gland Follicular Carcinoma; Stage III Thyroid Gland Papillary Carcinoma; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Oncocytic Follicular Carcinoma |
National Cancer Institute (NCI) |
2013-05-08 | PHASE2 |
| NCT01954745 | COMPLETED | Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma of the Extrahepatic Bile Duct |
Massachusetts General Hospital |
2013-09 | PHASE2 |
| NCT01865747 | COMPLETED | Renal Cell Carcinoma |
Exelixis |
2013-06 | PHASE3 |
| NCT01738438 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2013-02 | PHASE2 |
| NCT01553656 | COMPLETED | Solid Tumors; Cancer; NSCLC |
Exelixis |
2011-02 | PHASE1 |
| NCT01716715 | COMPLETED | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2012-11-06 | PHASE2 |
| NCT01703065 | TERMINATED | Adenocarcinoma of the Prostate; Castration-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
University of Washington |
2013-06-18 | PHASE2 |
| NCT01663272 | COMPLETED | Pancreatic Cancer |
University of Michigan Rogel Cancer Center |
2012-07 | PHASE1 |
| NCT01574937 | COMPLETED | Prostate Cancer |
Dana-Farber Cancer Institute |
2012-04-03 | PHASE1 |
| NCT01995058 | TERMINATED | Prostate Cancer; Castration Resistant Prostate Cancer; Prostatic Neoplasms |
Exelixis |
2014-02 | PHASE2 |
| NCT01428219 | TERMINATED | Prostate Cancer Metastatic |
University of Michigan Rogel Cancer Center |
2012-02 | PHASE2 |
| NCT01522443 | TERMINATED | Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms |
Exelixis |
2012-03 | PHASE3 |
| NCT01835184 | TERMINATED | Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2013-05 | PHASE1 |
| NCT01605227 | COMPLETED | Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms |
Exelixis |
2012-07 | PHASE3 |
| NCT01582295 | COMPLETED | Multiple Myeloma |
Massachusetts General Hospital |
2012-06 | PHASE1 |
| NCT01493869 | COMPLETED | Healthy; Hepatic Impairment |
Exelixis |
2011-09 | PHASE1 |
| NCT01347788 | COMPLETED | Prostate Adenocarcinoma |
Massachusetts General Hospital |
2011-04 | PHASE1 |
| NCT00940225 | COMPLETED | Solid Tumors; Cancer |
Exelixis |
2009-09 | PHASE2 |
| NCT01761773 | COMPLETED | Healthy; Renal Impairment |
Exelixis |
2012-12 | PHASE1 |
| NCT00960492 | COMPLETED | Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma |
Exelixis |
2009-09 | PHASE1 |
| NCT00596648 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Exelixis |
2008-02-12 | PHASE1; PHASE2 |
| NCT01100619 | COMPLETED | Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma |
Exelixis |
2010-04 | PHASE1 |
| NCT00704288 | COMPLETED | Glioblastoma Multiforme |
Exelixis |
2008-05 | PHASE2 |
| NCT00704730 | COMPLETED | Thyroid Cancer |
Exelixis |
2008-06 | PHASE3 |
| NCT01068782 | TERMINATED | Astrocytic Tumors |
Exelixis |
2010-04 | PHASE2 |
| NCT00215605 | COMPLETED | Lymphoma; Cancer; Thyroid Carcinoma |
Exelixis |
2005-09 | PHASE1 |
| NCT01018745 | COMPLETED | Neoplasms |
Bristol-Myers Squibb |
2010-01 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
Cabozantinib (XL184)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Cabozantinib (XL184) Mechanism of Action: VEGFR2 Inhibition in Endothelial Cells Research
- Cabozantinib (XL184): Selectivity & Specificity
- Cabozantinib (XL184) Working Concentration | Cell Culture | Treatment
- Cabozantinib (XL184) Solubility in DMSO
- Cabozantinib (XL184) Stock Solution
- Cabozantinib (XL184) Storage
- Cabozantinib (XL184) Stability
- Cabozantinib (XL184) Combination Database
- Cabozantinib (XL184) Molecular Weight
- Cabozantinib (XL184) SMILES
- Cabozantinib (XL184) CAS Number
- Cabozantinib (XL184) Chemical Structure (2D and 3D)
- Cabozantinib (XL184) IC50 for Cell-based and Cell-free Assays
- Cabozantinib (XL184) Sigma (SML3914)? Try a better option.
- Cabozantinib (XL184) MedChemExpress (HY-13016)? Try a better option.
- Cabozantinib (XL184) APExBIO (A2977)? Try a better option.
- Cabozantinib (XL184) Cayman (18464)? Try a better option.
- Cabozantinib (XL184) Tocris (5422)? Try a better option.
- Cabozantinib (XL184) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.